Is the Run in Biotechnology Stocks Over?

By Monday, March 25, 2013

Run in Biotechnology Stocks OverOne of the stock market’s strongest sectors over the last few years has been biotechnology stocks. It’s a very tough group in which to be a speculator, because you cannot predict discoveries or approvals. What you can do, though, is play the news flow while gauging sentiment in the stock market.

The NASDAQ Biotechnology Index has been on a tear for the last four years, and according to Reuters, the U.S. Food and Drug Administration (FDA) approved 39 new drugs and biological products last year. This compares to 30 in 2011 and 21 in 2010. It is the highest number, beating the previous high reached in 1996, when 35 new drugs were approved. (Source: Hirschler, B. and Humer, C., “FDA new drug approvals hit 16-year high in 2012,” Reuters, last accessed March 21, 2013.)

On the stock market, anything can happen with biotechnology stocks, and you can lose your shirt pretty quickly. Opko Health, Inc. (NYSE/OPK) is one of those biotechnology stocks that perfectly illustrate the challenges of trading in the group.

Opko is a biotechnology aggregator; it has its hand in a lot of developments. The company is run by Dr. Phillip Frost, who became a billionaire when he sold his last pharmaceutical company to a major drug manufacturer. Opko’s stock chart is featured below:

OPK Opko Health Inc stock market chart

Chart courtesy of www.StockCharts.com

For months and months, Frost was buying shares in Opko Health on the stock market (all open market, public and documented), but the price didn’t move. This went on and on until the company announced an expanded collaboration with Bristol Myers-Squibb Company (NYSE/BMY) for one of its diagnostic tests. Then, bam! Opko’s shares exploded on the stock market.

Biotechnology stocks are like this, but the tough part is that you have to be watching them all the time. (See “High Risk, High Reward—Two Great Companies for Traders.”) They can also move in the opposite direction with equal fervor.

The NASDAQ Biotechnology Index has continued momentum. The good thing about most biotechnology stocks is that they have little correlation to the broader stock market; they dance to their own tune, for sure.

Because there is so much money in pharmaceuticals, institutional participation within the sector is very strong. Among developing biotechnology stocks, virtually the only players are institutions (and billionaires).

A trader can piggyback on the news in biotechnology stocks, but you have to be prepared to quickly jump ship. The action in this group continues to have momentum, and FDA approvals should maintain a strong pace this year. The whole sector is, of course, 100% speculative.


About the Author | Browse Mitchell Clark's Articles

Mitchell Clark is a senior editor at Lombardi Financial, specializing in large- and micro-cap stocks. He’s the editor of a variety of popular Lombardi Financial newsletters, including Micro-Cap Reporter, Income for Life, Biotech Breakthrough Stock Report, and 100% Letter. Mitchell has been with Lombardi Financial for 17 years. He won the Jack Madden Prize in economic history and is a long-time student of equity markets. Prior to joining Lombardi, Mitchell was a stockbroker for a large investment bank. In the... Read Full Bio »

Sep. 3, 2015
Trailing 12-month EPS for Dow Jones companies (Most Recent Quarter) $1014.15
Trailing 12-month Price/earnings multiple (Most Recent Quarter)

17.44

Dow Jones Industrial Average Dividend Yield 2.71%
10-year U.S. Treasury Yield 2.14%

Immediate term outlook:
The bear market rally in stocks that started in March 2009, extended because of unprecedented central bank money printing, is coming to an end. Gold bullion is up $1,000 an ounce since we first recommended it in 2002 and we are still bullish on the physical metal.

Short-to-medium term outlook:
World economies are entering their slowest growth period since 2009. The Chinese economy grew last year at its slowest pace in 24 years. Japan is in recession. The eurozone is in depression. With almost half the S&P 500 companies deriving revenue outside the U.S., slower world economic growth will negatively impact revenue and earnings growth of American companies. Domestically, America’s gross domestic product grew by only a meager 2.3% in the second quarter, which will negatively impact an already overpriced equity market.

Poll

Will slowdown in China affect the U.S. economy?

View Results

Loading ... Loading ...
×
From: Michael Lombardi, MBA
Subject: Golden Opportunity for Stock Market Investors

Read this message